• Photo
Dr. Harvey Fineberg from the US, chairman of the International Health Regulations Review Committee

Dr. Harvey Fineberg from the US, chairman of the International Health Regulations Review Committee, briefs the press. (AP Photo/Keystone/Martial Trezzini)

  • More International News
In Cairo's City of the Dead, election brings hope
City of the Dead: election brings hope

As Egyptians took part in the country's first free presidential…

Egypt's 3rd runner-up calls for recount
Egypt's 3rd runner-up calls for recount

The third runner-up in Egypt's presidential race called …

Pope's butler arrested in scandal
Pope's butler arrested in scandal

The Vatican confirmed on Saturday that the pope's butler has …

Toll from Syrian attack more than 90
Toll from Syrian attack more than 90

Syria's opposition is calling on the U.N. Security Council to …

Mexican boy's eyes gouged out 'to save the world'
Boy's eyes gouged out 'to save world'

A 5-year-old Mexican boy whose eyes were allegedly gouged out …

Advertisement

Expert group to view swine flu papers

Finished report due out next year

Updated: Wednesday, 19 May 2010, 11:08 AM EDT
Published : Wednesday, 19 May 2010, 8:16 AM EDT

GENEVA (AP) - An expert panel investigating the World Health Organization's response to last year's swine flu outbreak said Wednesday it wants to see confidential exchanges between the U.N. body and drug companies.

The 29-member panel will seek WHO records and correspondence from before and after the H1N1 strain was declared a pandemic in June, said committee chairman Harvey Fineberg, who is also president of the Institute of Medicine in Washington.

"We will want to have access to certain confidential documents that may be in place here at WHO or elsewhere," Fineberg told reporters in Geneva.

The documents include "contractual or letters of understanding" between the pharmaceutical industry and WHO, he said. "Some of the agreements with industry that we would like to examine have been considered confidential," but so far all of the panel's requests have been met, he said.

WHO spokesman Gregory Hartl said he couldn't immediately comment.

Under criticism for how the outbreak was handled, WHO Director-General Margaret Chan convened the panel last month and urged its members to conduct a "credible and independent review" that she promised would be transparent.

The Geneva-based agency has denied allegations that it gave pharmaceutical companies privileged access to national decision-makers.

Governments around the world spent millions of dollars (euros) buying antiviral drugs and flu vaccines in anticipation of a serious outbreak that never happened.

Among the companies that benefited was Switzerland's Roche Group, which saw sales of its Tamiflu antiviral medication jump by 2 billion Swiss francs ($1.74 billion) last year. British firm GlaxoSmithKline PLC sold both vaccines and its antiviral Relenza, while France's Sanofi-Aventis SA and U.S.-based Baxter International made vaccines. Some companies donated medicine to poor countries.

WHO has confirmed 18,036 deaths from the H1N1 strain over the past year — far fewer than would have died from seasonal flu during the same period.

Chan said this week at a meeting of WHO's 193 member states that the world had been "just plain lucky" that swine flu wasn't deadlier.

The panel's final report is expected to be finished next year, and will be made public, Fineberg said.


Ground rules for posting comments: No profanity or personal attacks. Please comment on the subject of the story itself. If you do not follow these rules, we will remove your post. Keep it civil, folks!

Our commenting section is powered by IntenseDebate. If you registered for an account but didn't receive a verification e-mail, check your spam folder or click here for more information. For additional technical help, click here.

 

Advertisement
Advertisement
  • Site Tools